← The Wire
GLUENasdaq
Monte Rosa Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1826457
Develops molecular glue degraders to selectively destroy disease-causing proteins using AI and proprietary tools
$1.54B
Market cap
$23.90
Last close
+7.2%
1D
+28.0%
5D
1.8M
Volume
Price · last 39 sessions+22.1%
May 4L $16.37 · H $23.90Jun 29
98
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 11, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 29, 2026DEF 14ADEF 14AApr 29, 2026SC 13D/ASC 13D/AMar 19, 202610-K10-KMar 17, 20268-KResults of OperationsMar 17, 20268-KExecutive ChangeFeb 10, 20268-KMaterial Agreement · Company UpdateJan 9, 2026424B5424B5Jan 9, 2026SC 13D/ASC 13D/AJan 9, 20268-KCompany UpdateJan 7, 2026424B5424B5Jan 7, 20268-KReg FD Disclosure · Company UpdateJan 7, 20268-KReg FD Disclosure · Company UpdateDec 16, 202510-Q10-QNov 6, 20258-KResults of Operations · Reg FD DisclosureNov 6, 20258-KMaterial Agreement · Reg FD DisclosureSep 15, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KShareholder VoteJun 13, 202510-Q10-QMay 8, 20258-KResults of Operations · Reg FD DisclosureMay 8, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 202510-K10-KMar 20, 20258-KResults of Operations · Reg FD DisclosureMar 20, 20258-KResults of Operations · Reg FD DisclosureJan 10, 20258-KExecutive ChangeDec 13, 20248-KReg FD Disclosure · Company UpdateDec 5, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 20248-KMaterial Agreement · Reg FD DisclosureOct 28, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KReg FD DisclosureJun 27, 20248-KShareholder VoteJun 12, 20248-KExecutive Change · Reg FD DisclosureMay 30, 20248-KMaterial AgreementMay 16, 2024424B5424B5May 16, 2024424B5424B5May 15, 202410-Q10-QMay 9, 20248-KResults of Operations · Reg FD DisclosureMay 9, 20248-KExecutive Change · Reg FD DisclosureMay 2, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 202410-K10-KMar 14, 20248-KResults of Operations · Reg FD DisclosureMar 14, 2024SC 13GSC 13GFeb 14, 20248-KReg FD DisclosureJan 8, 202410-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KMaterial Agreement · Company UpdateOct 26, 2023424B5424B5Oct 26, 20238-KMaterial Agreement · Reg FD DisclosureOct 17, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KExecutive ChangeJul 26, 20238-KBylaw Amendment · Shareholder VoteJun 14, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 2023DEFA14ADEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 20238-KExecutive ChangeMar 23, 202310-K10-KMar 16, 20238-KResults of Operations · Reg FD DisclosureMar 16, 2023SC 13GSC 13GFeb 3, 20238-KReg FD DisclosureJan 9, 202310-Q10-QNov 10, 20228-KResults of OperationsNov 10, 20228-KReg FD DisclosureOct 24, 202210-Q10-QAug 11, 20228-KResults of OperationsAug 11, 20228-KShareholder VoteJun 15, 2022DEFA14ADEFA14AJun 8, 202210-Q10-QMay 11, 20228-KResults of OperationsMay 11, 2022DEFA14ADEFA14AApr 28, 2022DEF 14ADEF 14AApr 27, 2022
Insider Activity
In the 90 days to Mar 4, 2026: 6 sold $1.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Dunn EdmundPrincipal Accounting Officer | Sell | 139 | $17.96 | $2K |
| Mar 2, 2026 | Warmuth MarkusPresident & CEO | Sell | 5,466 | $17.92 | $98K |
| Mar 2, 2026 | Dunn EdmundPrincipal Accounting Officer | Sell | 536 | $17.50 | $9K |
| Feb 27, 2026 | Dunn EdmundPrincipal Accounting Officer | Sell | 25,164 | $18.10 | $455K |
| Feb 23, 2026 | Janku FilipChief Medical Officer | Sell | 9,189 | $19.50 | $179K |
| Jan 7, 2026 | Warmuth MarkusPresident & CEO | Sell | 3,707 | $23.24 | $86K |
| Jan 7, 2026 | Warmuth MarkusPresident & CEO | Sell | 1,450 | $23.88 | $35K |
| Jan 7, 2026 | Warmuth MarkusPresident & CEO | Sell | 309 | $24.57 | $8K |
| Jan 5, 2026 | Warmuth MarkusPresident & CEO | Sell | 10,135 | $15.17 | $154K |
| Jan 5, 2026 | Townson SharonChief Scientific Officer | Sell | 3,155 | $15.17 | $48K |
| Jan 5, 2026 | Nickson PhilipChief Business & Legal Officer | Sell | 3,155 | $15.17 | $48K |
| Jan 5, 2026 | Janku FilipChief Medical Officer | Sell | 3,155 | $15.17 | $48K |
| Jan 5, 2026 | Champoux JenniferChief Operating Officer | Sell | 2,629 | $15.17 | $40K |
| Jan 5, 2026 | Dunn EdmundPrincipal Accounting Officer | Sell | 1,039 | $15.17 | $16K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance